A nutraceutical strategy for downregulating TGFβ signalling: prospects for prevention of fibrotic disorders, including post-COVID- 19 pulmonary fibrosis

Research output: Contribution to journalArticlepeer-review

Abstract

Upregulated transforming growth factor-beta
(TGFβ) signalling, driving mesenchymal
cells to increase their production of ground
substance and undergo a transition to a
myofibroblast phenotype, is believed to play a
pathogenic role in diverse fibrotic disorders,
including benign prostatic hyperplasia, scleroderma,
pulmonary fibrosis, glomerulosclerosis,
tubulointerstial fibrosis, hepatic fibrosis,
open angle glaucoma, Peyronie’s disease and
the cardiac fibrosis associated with cardiac
hypertrophy and heart failure.1–20 It should
follow that safe, practical measures which
downregulate such signalling may have
potential for the prevention and control of
these syndromes. Nutraceutical measures
with this property have particular promise,
as they might be employed for primary
prevention. This issue is now of particular
interest, as pulmonary fibrosis is emerging as
a not-uncommon
long-term
complication of
COVID-19.21
Original languageEnglish
Article numbere001663
Pages (from-to)1-10
Number of pages10
JournalBMJ Open
Volume0
Issue numbere001663
StatePublished - 21 Mar 2021

Cite this